Kalderos

Optimizes drug discount management platform

Chicago, Illinois, United States

About Kalderos

Kalderos provides a platform designed to improve the management of drug discounts in the healthcare sector. This platform helps healthcare providers and pharmaceutical manufacturers accurately manage discount claims and avoid duplicate discounts. By using data analytics and machine learning, Kalderos simplifies the complicated process of drug discount management, making it more efficient and clear. Clients subscribe to the service, paying for access to the platform and its features, which include real-time data validation, detailed reporting tools, and automated compliance checks. These features assist clients in saving time and minimizing financial risks related to drug discount programs. Kalderos primarily serves large healthcare systems and pharmaceutical companies in the United States.

Chicago, IllinoisHeadquarters
2016Year Founded
$48.6MTotal Funding
LATE_VCCompany Stage
Consulting, AI & Machine Learning, HealthcareIndustries
51-200Employees

Benefits

Health Insurance
Dental Insurance
Vision Insurance
401(k) Company Match
401(k) Retirement Plan
Paid Vacation
Phone/Internet Stipend
Commuter Benefits
Home Office Stipend

Risks

Strategic shifts by new CSO Daryl Todd may disrupt existing operations.
Involvement in Arkansas litigation could lead to legal challenges or reputational damage.
Accountant shortage in the U.S. may impact Kalderos' financial reporting capabilities.

Differentiation

Kalderos offers a unique SaaS-based drug discount management solution.
The platform uses machine learning to detect inconsistencies in drug discount claims.
Kalderos provides real-time data validation and automated compliance checks.

Upsides

Growing demand for AI-driven compliance solutions in healthcare boosts Kalderos' market potential.
Expansion of 340B program compliance needs increases demand for Kalderos' services.
Collaboration opportunities with hospitals enhance Kalderos' drug discount management capabilities.

Funding

Total raised$48.57 M
Latest valuation$140.00 M
StageLATE_VC
LATE VC
8/31/2022
$15
$140.00 M
$28
$140.00 M
SERIES A
4/30/2019
$7
$35.00 M